Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Tiratricol
Imported (France)
Tiratricol
350microgram
Oral tablet
No Controlled Drug Status
Valid as a prescribable product
BNF:
Medical information – Emcitate® (tiratricol) Medical Department, Rare Thyroid Therapeutics International AB Medical Information Emcitate® – MCT8 Deficiency Ver 005 INSTRUCTION ON HOW TO REPORT AN ADVERSE DRUG REACTION AND PRODUCT INFORMATION EMCITATE® (TIRATRICOL) _EMCITATE IS NOT APPROVED FOR THE TREATMENT OF MCT8 DEFICIENCY ( ALSO KNOWN AS ALLAN-HERNDON- _ _DUDLEY SYNDROME) OR ANY OTHER INDICATION IN ANY COUNTRY. _ _TREATMENT WITH EMCITATE FOR A SPECIFIC PATIENT REQUIRES SPECIAL PERMISSION FROM THE NATIONAL _ _HEALTH/REGULATORY AUTHORITIES, WHICH IS APPLIED FOR BY THE PRESCRIBING PHYSICIAN. _ _ADVERSE EVENTS/ADVERSE DRUG REACTIONS SHOULD BE REPORTED TO SAFETY@EGETIS.COM BY USING THE _ _ATTACHED FORM _ _THE PRODUCT IS UNDER CONTINUED CLINICAL DEVELOPMENT. THIS PRODUCT INFORMATION ONLY REPRESENTS A _ _CONDENSED SUMMARY OF DATA CURRENTLY KNOWN AND IS ONLY PROVIDED BY THE MEDICAL DEPARTMENT ON _ _REQUEST FROM A HEALTH CARE PROFESSIONAL. _ _A GLOBAL REFERENCE CENTER FOR THE DIAGNOSIS AND MANAGEMENT OF MCT8 DEFICIENCY IS AVAILABLE AT THE _ _ERASMUS MEDICAL CENTER IN ROTTERDAM, THE NETHERLANDS. _ ACTIVE PHARMACEUTICAL INGREDIENT Tiratricol (3,3',5-triiodothyroacetic acid) PHARMACEUTICAL INFORMATION Emcitate 350 mcg (white, round) Other ingredients: calcium hydrogen phosphate, corn starch, lactose monohydrate, magnesium stearate. THERAPEUTIC EFFECTS Treatment of MCT8 deficiency, also known as the Allan-Herndon-Dudley Syndrome (AHDS) DOSAGE / POSOLOGY The tablets should be suspended in water before administration. The tablets do not need to be crushed or ground before suspension. The volume of water used to suspend the tablets should be adjusted to each individual dose (see Table 1). The suspension should be thoroughly mixed and immediately given to the participant either orally (if needed it can be mixed with mashed food or by PEG tube. If the participant can swallow food/liquid and is normally fed orally, the medication should be given either as a suspension, or by mixing the suspension with mashed food if Read the complete document